Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
Myeloperoxidase (MPO) activity has been associated with the metabolic syndrome, cardiovascular and liver disease. Here, we evaluate the therapeutic potential of MPO inhibition on nonalcoholic steatohepatitis (NASH) and NASH‐induced fibrosis, the main determinant of outcomes. MPO plasma levels were e...
Main Authors: | Anja Christina Koop, Nina Doreen Thiele, David Steins, Erik Michaëlsson, Malte Wehmeyer, Ludger Scheja, Babett Steglich, Samuel Huber, Julian Schulze zur Wiesch, Ansgar W. Lohse, Jörg Heeren, Johannes Kluwe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1566 |
Similar Items
-
TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice
by: Nina D. Thiele, et al.
Published: (2017-04-01) -
Metabolic-associated fatty liver disease and lipoprotein metabolism
by: Joerg Heeren, et al.
Published: (2021-08-01) -
The Clinical Perspective on Hepatitis E
by: Thomas Horvatits, et al.
Published: (2019-07-01) -
Treatment and re-treatment results of HCV patients in the DAA era.
by: Felix Piecha, et al.
Published: (2020-01-01) -
Characterization of the immune cell landscape of patients with NAFLD.
by: Tom Diedrich, et al.
Published: (2020-01-01)